Li Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Jiankun Wang
Department of Gastroenterology & General Surgery, The First Affiliated Hospital with Nanjing Medical University & Jiangsu Province Hospital, Nanjing, P.R. China
4 shared publicationsZhining Fan
Gastroenterology and General Surgery, The First Affiliated Hospital with Nanjing Medical University and Jiangsu Province Hospital, Nanjing, China
2 shared publicationsBangting Wang
Department of Gastroenterology & General Surgery, The First Affiliated Hospital with Nanjing Medical University & Jiangsu Province Hospital, Nanjing, P.R. China
1 shared publicationKexin He
Digestive Endoscopy Department and General Surgery Department, The First Affiliated Hospital with Nanjing Medical University and, Nanjing, China
1 shared publicationLili Zhao
Department of Gastroenterology & General Surgery, The First Affiliated Hospital with Nanjing Medical University & Jiangsu Province Hospital, Nanjing, P.R. China
1 shared publicationMin Wang
Department of Gastroenterology & General Surgery, The First Affiliated Hospital with Nanjing Medical University & Jiangsu Province Hospital, Nanjing, P.R. China
1 shared publication
Latest Publications
- 26 November 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (4) , 5818-5837
Potential Benefits of Metformin Via Roseburia Intestinalis in High-fat Diet-fed Mice With Colorectal Adenomas
Metformin (Met) is a pharmaceutical agent for the treatment of type 2 diabetes mellitus. Intriguingly, it may also play a role in the gastrointestinal tract, the gut microbial communities, and the tissue-resident immune cells. The present study aimed to investigate whether the administration of Met achieved protective effects on high-fat diet (HFD)-fed mice with colorectal adenomas (CRA) and elucidated its mechanism via the gut microbiota. AOM/DSS was administered in an HFD-induced diet to induce CRA in mice. 16 S rRNA sequencing was conducted to analyze the gut microbiota profile of mice. Met reduced the inflammatory response in the intestine and alleviated HFD-induced intestinal flora disturbances, and Roseburia intestinalis (R. intestinalis) colonization enhanced the efficacy of Met. Met suppressed CRA cell proliferation, which was further reduced by R. intestinalis. Met blocked NF-κB signaling by activating GILZ through increased R. intestinalis abundance. GILZ deletion in macrophages weakened the inhibition of CRA growth by Met and R. intestinalis, leading to increased macrophage M1 polarization. Inhibition of the NF-κB signaling reversed the activation of macrophage M1 polarization by knockdown of GILZ and reduced the proliferation of CRA cells. Our results shed light on the impact of Met on gut microbiome alteration in treating CRA.
- 26 November 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (4) , 5818-5837
Potential Benefits of Metformin Via Roseburia Intestinalis in High-fat Diet-fed Mice With Colorectal Adenomas
Metformin (Met) is a pharmaceutical agent for the treatment of type 2 diabetes mellitus. Intriguingly, it may also play a role in the gastrointestinal tract, the gut microbial communities, and the tissue-resident immune cells. The present study aimed to investigate whether the administration of Met achieved protective effects on high-fat diet (HFD)-fed mice with colorectal adenomas (CRA) and elucidated its mechanism via the gut microbiota. AOM/DSS was administered in an HFD-induced diet to induce CRA in mice. 16 S rRNA sequencing was conducted to analyze the gut microbiota profile of mice. Met reduced the inflammatory response in the intestine and alleviated HFD-induced intestinal flora disturbances, and Roseburia intestinalis (R. intestinalis) colonization enhanced the efficacy of Met. Met suppressed CRA cell proliferation, which was further reduced by R. intestinalis. Met blocked NF-κB signaling by activating GILZ through increased R. intestinalis abundance. GILZ deletion in macrophages weakened the inhibition of CRA growth by Met and R. intestinalis, leading to increased macrophage M1 polarization. Inhibition of the NF-κB signaling reversed the activation of macrophage M1 polarization by knockdown of GILZ and reduced the proliferation of CRA cells. Our results shed light on the impact of Met on gut microbiome alteration in treating CRA.
- 28 October 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (11) , 1317-1318
Is the underwater injection endoscopic mucosal resection technique suitable for T1 colorectal cancer?
10.1055/a-2479-9227 We read the article by Hirai et al. [1] with great interest and appreciate the authors' innovative approach; however, we would like to raise several concerns and seek clarification on a few points. First, when evaluating the feasibility of a novel technique, the study design should ideally be prospective. Retrospective studies are more appropriate for well-established methods [2]. Therefore, a prospective study should be conducted initially to adequately assess the safety and efficacy of the new technique before performing retrospective analyses. Second, according to the European Society of Gastrointestinal Endoscopy (ESGE) guidelines, endoscopic submucosal dissection (ESD) should be considered for colorectal lesions with suspected submucosal invasion, particularly those >20 mm [3]. In the study reported by Hirai et al., some T1 colorectal cancers (CRCs) exceeded 20 mm in diameter. It remains unclear why underwater injection endoscopic mucosal resection (UIEMR) was still selected for these cases. Although UIEMR demonstrates a relatively high en bloc resection rate, its R0 resection rate is lower, increasing the likelihood of Rx resection. In such cases, ESD or hybrid ESD might be more appropriate options. Third, in order to evaluate whether the novel technique can achieve adequate vertical margins in T1 CRC, the authors included 135 lesions in total, of which only seven were histologically confirmed to be T1 CRC. Drawing conclusions from such a limited number of relevant cases may compromise the reliability of the findings. Inclusion of a larger cohort of confirmed T1 CRC cases is necessary for more robust conclusions. Lastly, among the seven T1 CRC lesions, several showed submucosal invasion depths >3000 μm, and the vertical margin distance extended even further. This raises the question of whether the UIEMR resection depth may have exceeded the submucosal layer and potentially damaged the muscularis propria [4]. In conclusion, despite these concerns, UIEMR appears to offer a promising new approach for the resection of colorectal polyps ≥10 mm and warrants further clinical investigation and validation. Article published online: 28 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 28 October 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (11) , 1317-1318
Is the underwater injection endoscopic mucosal resection technique suitable for T1 colorectal cancer?
10.1055/a-2479-9227 We read the article by Hirai et al. [1] with great interest and appreciate the authors' innovative approach; however, we would like to raise several concerns and seek clarification on a few points. First, when evaluating the feasibility of a novel technique, the study design should ideally be prospective. Retrospective studies are more appropriate for well-established methods [2]. Therefore, a prospective study should be conducted initially to adequately assess the safety and efficacy of the new technique before performing retrospective analyses. Second, according to the European Society of Gastrointestinal Endoscopy (ESGE) guidelines, endoscopic submucosal dissection (ESD) should be considered for colorectal lesions with suspected submucosal invasion, particularly those >20 mm [3]. In the study reported by Hirai et al., some T1 colorectal cancers (CRCs) exceeded 20 mm in diameter. It remains unclear why underwater injection endoscopic mucosal resection (UIEMR) was still selected for these cases. Although UIEMR demonstrates a relatively high en bloc resection rate, its R0 resection rate is lower, increasing the likelihood of Rx resection. In such cases, ESD or hybrid ESD might be more appropriate options. Third, in order to evaluate whether the novel technique can achieve adequate vertical margins in T1 CRC, the authors included 135 lesions in total, of which only seven were histologically confirmed to be T1 CRC. Drawing conclusions from such a limited number of relevant cases may compromise the reliability of the findings. Inclusion of a larger cohort of confirmed T1 CRC cases is necessary for more robust conclusions. Lastly, among the seven T1 CRC lesions, several showed submucosal invasion depths >3000 μm, and the vertical margin distance extended even further. This raises the question of whether the UIEMR resection depth may have exceeded the submucosal layer and potentially damaged the muscularis propria [4]. In conclusion, despite these concerns, UIEMR appears to offer a promising new approach for the resection of colorectal polyps ≥10 mm and warrants further clinical investigation and validation. Article published online: 28 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 22 April 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (05) , 572-573
Comments on “Local triamcinolone injection and selective add-on oral steroids to prevent esophageal post-endoscopic submucosal dissection stricture”
We read with great interest the article by Carpentier et al. [1] reporting the use of local triamcinolone injection and selective add-on oral steroids to prevent esophageal post-endoscopic submucosal dissection (ESD) stricture; however, we have some comments regarding this study. First, this study included three groups of patients categorized on the basis of the degree of circumferential resection (<50%, 50%–89%, and ≥90%); however, both the previous literature [2] and the data from this study have indicated that the incidence of postoperative stricture is minimal for patients with circumferential resections of <50%. Furthermore, the authors did not provide any specific postoperative management for this group. Including these patients appeared unnecessary and might have artificially lowered the overall incidence of postoperative strictures. Second, previous studies have reported post-ESD esophageal stricture rates for resections involving more than 50%, 75%, and 90% of the esophageal circumference [3], but the grouping used in the study of Carpentier et al. was 50%–89% and ≥90%. As this study was a noncomparative retrospective study, its results can only be compared with the previous literature. This inconsistency in the grouping compared with most prior studies made it challenging to evaluate the feasibility of the findings. Third, the study reported 111 patients who underwent 130 ESD procedures, implying that some patients underwent multiple ESDs. If postoperative strictures occurred in these patients, how was it determined which ESD site caused the stricture? Would multiple ESDs have influenced the incidence of postoperative strictures? During patient selection, would it not have been more appropriate to include only patients who underwent a single ESD? Fourth, during the study, patients were continuously censored for various reasons, and endoscopic follow-up at 3–6 months was available for only 58% of patients (75/130). The authors used the total number of ESD procedures as the denominator, instead of the total number of patients, which is confusing. Does the high rate of loss to follow-up compromise the reliability of these results? In general, although this research had several limitations, it still provided useful clinical evidence of a systematic steroid administration protocol for post-ESD stricture prevention in a Western center. Article published online: 22 April 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 22 April 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (05) , 572-573
Comments on “Local triamcinolone injection and selective add-on oral steroids to prevent esophageal post-endoscopic submucosal dissection stricture”
We read with great interest the article by Carpentier et al. [1] reporting the use of local triamcinolone injection and selective add-on oral steroids to prevent esophageal post-endoscopic submucosal dissection (ESD) stricture; however, we have some comments regarding this study. First, this study included three groups of patients categorized on the basis of the degree of circumferential resection (<50%, 50%–89%, and ≥90%); however, both the previous literature [2] and the data from this study have indicated that the incidence of postoperative stricture is minimal for patients with circumferential resections of <50%. Furthermore, the authors did not provide any specific postoperative management for this group. Including these patients appeared unnecessary and might have artificially lowered the overall incidence of postoperative strictures. Second, previous studies have reported post-ESD esophageal stricture rates for resections involving more than 50%, 75%, and 90% of the esophageal circumference [3], but the grouping used in the study of Carpentier et al. was 50%–89% and ≥90%. As this study was a noncomparative retrospective study, its results can only be compared with the previous literature. This inconsistency in the grouping compared with most prior studies made it challenging to evaluate the feasibility of the findings. Third, the study reported 111 patients who underwent 130 ESD procedures, implying that some patients underwent multiple ESDs. If postoperative strictures occurred in these patients, how was it determined which ESD site caused the stricture? Would multiple ESDs have influenced the incidence of postoperative strictures? During patient selection, would it not have been more appropriate to include only patients who underwent a single ESD? Fourth, during the study, patients were continuously censored for various reasons, and endoscopic follow-up at 3–6 months was available for only 58% of patients (75/130). The authors used the total number of ESD procedures as the denominator, instead of the total number of patients, which is confusing. Does the high rate of loss to follow-up compromise the reliability of these results? In general, although this research had several limitations, it still provided useful clinical evidence of a systematic steroid administration protocol for post-ESD stricture prevention in a Western center. Article published online: 22 April 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 27 June 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (07) , 551-552
Visualized biliary cannulation during ERCP: do we really need it?
We read with great interest the article by Liu et al. [1] reporting their initial experience of visualized biliary cannulation during endoscopic retrograde cholangiopancreatography (ERCP); however, we have several questions about the study. First, as mentioned in the article, although the ERCP technique is difficult, the success rate of cannulation is now very high for experienced endoscopists [2]. Visualized biliary cannulation does not simplify the ERCP procedure, instead it requires further learning to perform cholangioscopy on top of mastering ERCP and also increases the costs significantly. Therefore, for most situations, visualized biliary cannulation is not necessary. It is necessary only for patients with difficult cannulation or those who cannot undergo radiographic examination. The inclusion criteria for this study should have been patients in this category, and the results would have been more meaningful. Second, our center has also performed numerous cholangioscopy procedures. For complex cholangioscopy procedures, in addition to control of the direction of the duodenoscope and the insertion and withdrawal of the cholangioscope by the operator, an experienced assistant is also required to manipulate the direction of the cholangioscope. Compared with traditional ERCP, it therefore requires more manpower. For complex procedures such as visualized biliary cannulation, we wonder how many operators your center typically requires? Third, this study is not a controlled trial, so comparing it to the previous literature [3] alone cannot prove that the cannulation success rate is higher and the postoperative complications fewer. Moreover, the operators chosen to perform this study were experienced endoscopists with extensive traditional ERCP experience but even they, at the learning stage, still had some limitations, demonstrating that this technique is more difficult than traditional ERCP. Overall, cholangioscopy is a revolutionary technology that helps us address some areas where traditional ERCP is lacking, particularly in the diagnosis and treatment of bile duct strictures and refractory stones; however, it requires higher operator expertise and there should be some selectivity in its application. It cannot be blindly expanded for new indications and cannot completely replace traditional ERCP. Article published online: 27 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 June 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (07) , 551-552
Visualized biliary cannulation during ERCP: do we really need it?
We read with great interest the article by Liu et al. [1] reporting their initial experience of visualized biliary cannulation during endoscopic retrograde cholangiopancreatography (ERCP); however, we have several questions about the study. First, as mentioned in the article, although the ERCP technique is difficult, the success rate of cannulation is now very high for experienced endoscopists [2]. Visualized biliary cannulation does not simplify the ERCP procedure, instead it requires further learning to perform cholangioscopy on top of mastering ERCP and also increases the costs significantly. Therefore, for most situations, visualized biliary cannulation is not necessary. It is necessary only for patients with difficult cannulation or those who cannot undergo radiographic examination. The inclusion criteria for this study should have been patients in this category, and the results would have been more meaningful. Second, our center has also performed numerous cholangioscopy procedures. For complex cholangioscopy procedures, in addition to control of the direction of the duodenoscope and the insertion and withdrawal of the cholangioscope by the operator, an experienced assistant is also required to manipulate the direction of the cholangioscope. Compared with traditional ERCP, it therefore requires more manpower. For complex procedures such as visualized biliary cannulation, we wonder how many operators your center typically requires? Third, this study is not a controlled trial, so comparing it to the previous literature [3] alone cannot prove that the cannulation success rate is higher and the postoperative complications fewer. Moreover, the operators chosen to perform this study were experienced endoscopists with extensive traditional ERCP experience but even they, at the learning stage, still had some limitations, demonstrating that this technique is more difficult than traditional ERCP. Overall, cholangioscopy is a revolutionary technology that helps us address some areas where traditional ERCP is lacking, particularly in the diagnosis and treatment of bile duct strictures and refractory stones; however, it requires higher operator expertise and there should be some selectivity in its application. It cannot be blindly expanded for new indications and cannot completely replace traditional ERCP. Article published online: 27 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany